⚡ Flash Summary

Highnoon Laboratories Limited’s (HINOON) unconsolidated financial results for the quarter ended September 30, 2025, show positive revenue growth and profitability. Revenue from contracts with customers increased to PKR 18.61 billion from PKR 16.96 billion in the same period last year. Profit after tax for the period also increased to PKR 2.63 billion compared to PKR 2.36 billion in the prior year, driven by effective cost management and increased operational efficiency. The company’s earnings per share (EPS) grew to PKR 49.61 compared to PKR 44.54, highlighting enhanced shareholder value.

📌 Key Takeaways

• 🚀 Revenue from contracts with customers grew by 9.78%, reaching PKR 18.61 billion compared to PKR 16.96 billion in 2024.
• 💰 Gross profit increased by 22.21%, from PKR 8.38 billion in 2024 to PKR 10.24 billion in 2025.
• 📈 Profit from operations rose by 24.17%, from PKR 3.12 billion to PKR 3.88 billion.
• 💸 Other income increased marginally by 1.78%, from PKR 326.80 million to PKR 332.61 million.
• 📉 Finance costs decreased significantly by 45.79%, from PKR 169.05 million to PKR 91.13 million.
• ✅ Profit before income tax increased by 25.57%, from PKR 3.27 billion to PKR 4.12 billion.
• 🧾 Taxation expenses increased by 63.68%, from PKR 912.21 million to PKR 1.49 billion.
• 🌟 Profit after tax for the period rose by 11.37%, from PKR 2.36 billion to PKR 2.63 billion.
• ✔️ Basic and diluted earnings per share (EPS) increased by 11.38%, from PKR 44.54 to PKR 49.61.
• Balance sheet shows an increase in total assets from PKR 16.06 billion in Dec 2024 to PKR 16.97 billion in Sept 2025
• Equity increased to PKR 11.73 billion compared to PKR 11.22 billion at the end of the prior year
• No cash or bonus dividends have been announced

🎯 Investment Thesis

Highnoon Laboratories presents a BUY opportunity due to its strong financial performance, consistent growth, and effective cost management. The company’s increased revenue, improved profitability, and enhanced earnings per share make it an attractive investment. With a positive outlook for the pharmaceutical sector in Pakistan, HINOON is well-positioned to continue its growth trajectory.